Capricor Therapeutics (CAPR) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CAPR Stock Forecast

Capricor Therapeutics stock forecast is as follows: an average price target of $15.38 (represents a 17.67% upside from CAPR’s last price of $13.07) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

CAPR Price Target

The average price target for Capricor Therapeutics (CAPR) is $15.38 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $21.50 to $10.00. This represents a potential 17.67% upside from CAPR's last price of $13.07.

CAPR Analyst Ratings

Buy

According to 6 Wall Street analysts, Capricor Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CAPR stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Capricor Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 21, 2024	Edward Tenthoff	Piper Sandler	$17.50	$9.43	85.58%	33.89%
Oct 14, 2024	Leland Gershall	Oppenheimer	$21.50	$8.89	141.84%	64.50%
Sep 25, 2024	Jason McCarthy	Maxim Group	$12.50	$4.55	174.73%	-4.36%
Sep 25, 2024	Joseph Pantginis	H.C. Wainwright	$10.00	$2.78	259.71%	-23.49%
Sep 17, 2024	Leland Gershall	Oppenheimer	$7.50	$2.54	195.28%	-42.62%
May 16, 2024	Leland Gershall	Oppenheimer	$7.00	$2.82	148.23%	-46.44%

The latest Capricor Therapeutics stock forecast, released on Oct 21, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $17.50, which represents a 85.58% increase from the stock price at the time of the forecast ($9.43), and a 33.89% increase from CAPR last price ($13.07).

Capricor Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	4	6
Avg Price Target	-	$15.38	$12.67
Last Closing Price	$13.07	$13.07	$13.07
Upside/Downside	-100.00%	17.67%	-3.06%

In the current month, the average price target of Capricor Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Capricor Therapeutics's last price of $13.07. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 21, 2024	Piper Sandler		Overweight	Initialise
Oct 14, 2024	Oppenheimer	Outperform	Outperform	Hold
Oct 11, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 25, 2024	Maxim Group	Buy	Buy	Hold
Sep 24, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
Sep 20, 2024	Oppenheimer	Buy	Buy	Hold
Sep 18, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 17, 2024	Oppenheimer	Outperform	Outperform	Hold
Jul 02, 2024	Oppenheimer	Buy	Buy	Hold
Jul 02, 2024	H.C. Wainwright	Buy	Buy	Hold
May 16, 2024	Oppenheimer		Outperform	Initialise
May 14, 2024	Ladenburg Thalmann & Co.	Buy	Buy	Hold

Capricor Therapeutics's last stock rating was published by Piper Sandler on Oct 21, 2024. The company Initialise its CAPR rating from "null" to "Overweight".

Capricor Therapeutics Financial Forecast

Capricor Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Sep 21	Jun 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Sep 14
Revenue	-	-	-	-	-	-	-	-	$12.09M	$6.19M	$3.92M	$2.99M	$957.35K	$1.59M	-	-	$204.08K	$57.83K	$16.86K	$49.86K	$185.69K	$222.10K	$142.07K	$410.35K	$230.50K	$400.07K	$880.81K	$1.22M	$1.79M	$1.30M
Avg Forecast	$6.23M	$2.17M	$2.17M	$2.17M	$11.52M	$4.28M	$4.58M	$9.70M	$10.60M	$3.15M	$3.00M	$1.00M	$10.00K	$420.00K	$390.00K	$210.00K	$210.00K	$210.00K	$210.00K	$210.00K	$210.00K	$70.00K	$220.00K	$220.00K	$430.00K	$342.86K	$776.47K	$891.54K	$1.58M	$2.20M
High Forecast	$6.71M	$2.33M	$2.33M	$2.33M	$12.59M	$4.38M	$4.93M	$10.45M	$11.42M	$3.39M	$3.23M	$1.08M	$10.77K	$420.00K	$390.00K	$210.00K	$210.00K	$210.00K	$210.00K	$210.00K	$210.00K	$70.00K	$220.00K	$220.00K	$430.00K	$411.43K	$931.76K	$1.07M	$1.90M	$2.64M
Low Forecast	$5.75M	$2.00M	$2.00M	$2.00M	$10.80M	$4.18M	$4.23M	$8.95M	$9.78M	$2.91M	$2.77M	$923.08K	$9.23K	$420.00K	$390.00K	$210.00K	$210.00K	$210.00K	$210.00K	$210.00K	$210.00K	$70.00K	$220.00K	$220.00K	$430.00K	$274.28K	$621.17K	$713.23K	$1.26M	$1.76M
# Analysts	1	1	1	2	5	4	1	1	2	1	1	1	1	1	1	1	1	11	15	9	9	8	8	12	16	19	8	11	11	11
Surprise %	-	-	-	-	-	-	-	-	1.14%	1.96%	1.31%	2.99%	95.74%	3.79%	-	-	0.97%	0.28%	0.08%	0.24%	0.88%	3.17%	0.65%	1.87%	0.54%	1.17%	1.13%	1.36%	1.13%	0.59%

Capricor Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $9.70M, with a low forecast of $8.95M, and a high forecast of $10.45M. CAPR's average Quarter revenue forecast represents a -19.76% decrease compared to the company's last Quarter revenue of $12.09M (Dec 23).

Capricor Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Sep 21	Jun 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Sep 14
# Analysts	1	1	1	2	5	4	1	1	2	1	1	1	1	1	1	1	1	11	15	9	9	8	8	12	16	19	8	11	11	11
EBITDA	-	-	-	-	-	-	-	-	$-1.06M	$-6.86M	$-8.13M	$-8.60M	$-8.41M	$-6.45M	$-7.34M	$-3.87M	$-4.70M	$-4.14M	$-3.87M	$-3.45M	$-2.05M	$-1.43M	$-1.56M	$-2.00M	$-2.48M	$-3.64M	$-3.52M	$-4.17M	$-3.39M	$-1.47M
Avg Forecast	$-6.13M	$-2.13M	$-2.13M	$-2.13M	$-11.32M	$-4.21M	$-4.50M	$-9.53M	$-10.42M	$-3.10M	$-2.95M	$-982.77K	$-9.83K	$-412.76K	$-383.28K	$-206.38K	$-5.10M	$-206.38K	$-206.38K	$-206.38K	$-2.24M	$-68.79K	$-216.21K	$-2.53M	$-422.59K	$-3.03M	$-3.05M	$-2.63M	$-2.94M	$-1.87M
High Forecast	$-5.65M	$-1.97M	$-1.97M	$-1.97M	$-10.61M	$-4.11M	$-4.15M	$-8.80M	$-9.62M	$-2.86M	$-2.72M	$-907.17K	$-9.07K	$-412.76K	$-383.28K	$-206.38K	$-4.08M	$-206.38K	$-206.38K	$-206.38K	$-1.79M	$-68.79K	$-216.21K	$-2.02M	$-422.59K	$-2.42M	$-2.44M	$-2.11M	$-2.36M	$-1.49M
Low Forecast	$-6.60M	$-2.29M	$-2.29M	$-2.29M	$-12.38M	$-4.30M	$-4.85M	$-10.27M	$-11.22M	$-3.33M	$-3.18M	$-1.06M	$-10.58K	$-412.76K	$-383.28K	$-206.38K	$-6.13M	$-206.38K	$-206.38K	$-206.38K	$-2.69M	$-68.79K	$-216.21K	$-3.04M	$-422.59K	$-3.64M	$-3.66M	$-3.16M	$-3.53M	$-2.24M
Surprise %	-	-	-	-	-	-	-	-	0.10%	2.22%	2.76%	8.75%	855.99%	15.62%	19.16%	18.74%	0.92%	20.04%	18.77%	16.72%	0.92%	20.74%	7.23%	0.79%	5.86%	1.20%	1.15%	1.58%	1.15%	0.79%

undefined analysts predict CAPR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Capricor Therapeutics's previous annual EBITDA (undefined) of $NaN.

Capricor Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Sep 21	Jun 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Sep 14
# Analysts	1	1	1	2	5	4	1	1	2	1	1	1	1	1	1	1	1	11	15	9	9	8	8	12	16	19	8	11	11	11
Net Income	-	-	-	-	-	-	-	-	$-762.09K	$-6.39M	$-7.37M	$408.67M	$-7.83M	$-6.26M	$-6.90M	$-3.93M	$-4.75M	$-4.18M	$-3.91M	$-3.48M	$-2.08M	$-1.47M	$-1.61M	$-2.05M	$-2.52M	$-3.67M	$-3.67M	$-4.27M	$-3.48M	$-1.54M
Avg Forecast	$-10.48M	$-12.79M	$-13.02M	$-12.02M	$-5.86M	$-11.86M	$-11.78M	$-3.76M	$-2.98M	$-10.04M	$-11.58M	$-10.59M	$-11.25M	$-10.19M	$-8.12M	$-7.32M	$-5.16M	$-6.37M	$-5.73M	$-10.83M	$-2.27M	$-10.83M	$-21.65M	$-2.58M	$-35.03M	$-3.06M	$-3.18M	$-2.69M	$-3.02M	$-1.96M
High Forecast	$-9.43M	$-11.52M	$-11.71M	$-10.31M	$-5.33M	$-10.67M	$-10.60M	$-3.39M	$-2.68M	$-9.03M	$-10.42M	$-9.53M	$-10.13M	$-10.19M	$-8.12M	$-7.32M	$-4.13M	$-6.37M	$-5.73M	$-10.83M	$-1.82M	$-10.83M	$-21.65M	$-2.07M	$-35.03M	$-2.45M	$-2.54M	$-2.16M	$-2.42M	$-1.57M
Low Forecast	$-11.53M	$-14.07M	$-14.32M	$-13.40M	$-6.57M	$-13.04M	$-12.96M	$-4.14M	$-3.28M	$-11.04M	$-12.74M	$-11.65M	$-12.38M	$-10.19M	$-8.12M	$-7.32M	$-6.19M	$-6.37M	$-5.73M	$-10.83M	$-2.73M	$-10.83M	$-21.65M	$-3.10M	$-35.03M	$-3.67M	$-3.81M	$-3.23M	$-3.62M	$-2.35M
Surprise %	-	-	-	-	-	-	-	-	0.26%	0.64%	0.64%	-38.59%	0.70%	0.61%	0.85%	0.54%	0.92%	0.66%	0.68%	0.32%	0.92%	0.14%	0.07%	0.79%	0.07%	1.20%	1.15%	1.58%	1.15%	0.79%

Capricor Therapeutics's average Quarter net income forecast for Jun 23 is $-11.58M, with a range of $-12.74M to $-10.42M. CAPR's average Quarter net income forecast represents a -102.83% decrease compared to the company's last Quarter net income of $408.67M (Mar 23).

Capricor Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Sep 21	Jun 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Sep 14
# Analysts	1	1	1	2	5	4	1	1	2	1	1	1	1	1	1	1	1	11	15	9	9	8	8	12	16	19	8	11	11	11
SG&A	-	-	-	-	-	-	-	-	$3.21M	$3.02M	$2.85M	$3.51M	$2.79M	$2.56M	$2.36M	$1.80M	$1.79M	$1.49M	$1.30M	$1.61M	$1.14M	$876.72K	$911.97K	$831.93K	$976.49K	$1.39M	$1.19M	$1.08M	$1.40M	$819.68K
Avg Forecast	$71.20M	$24.75M	$24.75M	$24.75M	$131.53M	$48.91M	$52.32M	$110.80M	$121.08M	$35.98M	$34.27M	$11.42M	$114.23K	$4.80M	$4.45M	$2.40M	$2.40M	$2.40M	$2.40M	$2.40M	$2.40M	$799.59K	$2.51M	$2.51M	$4.91M	$3.92M	$8.87M	$685.07K	$1.21M	$1.04M
High Forecast	$76.68M	$26.65M	$26.65M	$26.65M	$143.86M	$50.03M	$56.34M	$119.32M	$130.39M	$38.75M	$36.90M	$12.30M	$123.01K	$4.80M	$4.45M	$2.40M	$2.40M	$2.40M	$2.40M	$2.40M	$2.40M	$799.59K	$2.51M	$2.51M	$4.91M	$4.70M	$10.64M	$822.09K	$1.45M	$1.25M
Low Forecast	$65.72M	$22.85M	$22.85M	$22.85M	$123.31M	$47.79M	$48.29M	$102.28M	$111.77M	$33.21M	$31.63M	$10.54M	$105.43K	$4.80M	$4.45M	$2.40M	$2.40M	$2.40M	$2.40M	$2.40M	$2.40M	$799.59K	$2.51M	$2.51M	$4.91M	$3.13M	$7.10M	$548.06K	$969.83K	$831.61K
Surprise %	-	-	-	-	-	-	-	-	0.03%	0.08%	0.08%	0.31%	24.46%	0.53%	0.53%	0.75%	0.75%	0.62%	0.54%	0.67%	0.47%	1.10%	0.36%	0.33%	0.20%	0.35%	0.13%	1.58%	1.15%	0.79%

Capricor Therapeutics's average Quarter SG&A projection for Mar 24 is $110.80M, based on 1 Wall Street analysts, with a range of $102.28M to $119.32M. The forecast indicates a 3350.70% rise compared to CAPR last annual SG&A of $3.21M (Dec 23).

Capricor Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Sep 21	Jun 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Sep 14
# Analysts	1	1	1	2	5	4	1	1	2	1	1	1	1	1	1	1	1	11	15	9	9	8	8	12	16	19	8	11	11	11
EPS	-	-	-	-	-	-	-	-	$-0.02	$-0.25	$-0.29	$16.19	$-0.31	$-0.26	$-0.28	$-0.17	$-0.21	$-0.21	$-0.20	$-0.23	$-0.30	$-0.34	$-0.43	$-0.59	$-0.80	$-1.40	$-1.70	$-2.60	$-2.30	$-1.30
Avg Forecast	$-0.32	$-0.39	$-0.39	$-0.36	$-0.18	$-0.36	$-0.36	$-0.11	$-0.09	$-0.30	$-0.35	$-0.32	$-0.34	$-0.32	$-0.26	$-0.23	$-0.23	$-0.20	$-0.18	$-0.34	$-0.36	$-0.34	$-0.68	$-0.80	$-1.10	$-1.00	$-0.13	$-0.12	$-0.12	$-0.28
High Forecast	$-0.28	$-0.35	$-0.35	$-0.31	$-0.16	$-0.32	$-0.32	$-0.10	$-0.08	$-0.27	$-0.32	$-0.29	$-0.31	$-0.32	$-0.26	$-0.23	$-0.23	$-0.20	$-0.18	$-0.34	$-0.36	$-0.34	$-0.68	$-0.80	$-1.10	$-0.80	$-0.10	$-0.10	$-0.10	$-0.22
Low Forecast	$-0.35	$-0.43	$-0.43	$-0.40	$-0.20	$-0.39	$-0.39	$-0.13	$-0.10	$-0.33	$-0.39	$-0.35	$-0.37	$-0.32	$-0.26	$-0.23	$-0.23	$-0.20	$-0.18	$-0.34	$-0.36	$-0.34	$-0.68	$-0.80	$-1.10	$-1.20	$-0.16	$-0.14	$-0.15	$-0.33
Surprise %	-	-	-	-	-	-	-	-	0.28%	0.82%	0.83%	-50.59%	0.91%	0.81%	1.10%	0.74%	0.91%	1.05%	1.11%	0.68%	0.83%	1.00%	0.63%	0.74%	0.73%	1.40%	13.08%	21.67%	19.17%	4.64%

According to 1 Wall Street analysts, Capricor Therapeutics's projected average Quarter EPS for Jun 23 is $-0.35, with a low estimate of $-0.39 and a high estimate of $-0.32. This represents a -102.16% decrease compared to CAPR previous annual EPS of $16.19 (Mar 23).

Capricor Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
AKTX	Akari Therapeutics	$1.00	$30.00	2900.00%
KROS	Keros Therapeutics	$18.00	$102.00	466.67%	Buy
NXTC	NextCure	$0.90	$3.00	233.33%	Buy
ANAB	AnaptysBio	$15.99	$49.83	211.63%	Buy
IDYA	IDEAYA Biosciences	$26.33	$53.33	102.54%	Buy
SLNO	Soleno Therapeutics	$47.65	$69.67	46.21%	Buy
MGTX	MeiraGTx	$6.40	$9.00	40.63%	Buy
CAPR	Capricor Therapeutics	$13.20	$15.38	16.52%	Buy
CDTX	Cidara Therapeutics	$22.81	$12.00	-47.39%	Buy

CAPR Forecast FAQ

Is Capricor Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Capricor Therapeutics (CAPR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of CAPR's total ratings.

What is CAPR's price target?

Capricor Therapeutics (CAPR) average price target is $15.38 with a range of $10 to $21.5, implying a 17.67% from its last price of $13.07. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Capricor Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CAPR stock, the company can go up by 17.67% (from the last price of $13.07 to the average price target of $15.38), up by 64.50% based on the highest stock price target, and down by -23.49% based on the lowest stock price target.

Can Capricor Therapeutics stock reach $20?

CAPR's highest twelve months analyst stock price target of $21.5 supports the claim that Capricor Therapeutics can reach $20 in the near future.

What are Capricor Therapeutics's analysts' financial forecasts?

Capricor Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $30.08M (high $32.35M, low $28.16M), average EBITDA is $-29.559M (high $-27.676M, low $-31.796M), average net income is $-33.261M (high $-29.989M, low $-36.711M), average SG&A $343.56M (high $369.56M, low $321.67M), and average EPS is $-1.005 (high $-0.906, low $-1.109). CAPR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $12.73M (high $13.71M, low $11.75M), average EBITDA is $-12.514M (high $-11.551M, low $-13.477M), average net income is $-48.311M (high $-42.965M, low $-53.314M), average SG&A $145.45M (high $156.64M, low $134.26M), and average EPS is $-1.46 (high $-1.298, low $-1.611).

Did the CAPR's actual financial results beat the analysts' financial forecasts?

Based on Capricor Therapeutics's last annual report (Dec 2023), the company's revenue was $25.18M, beating the average analysts forecast of $17.75M by 41.85%. Apple's EBITDA was $-23.86M, beating the average prediction of $-17.444M by 36.78%. The company's net income was $-22.288M, missing the average estimation of $-35.186M by -36.66%. Apple's SG&A was $12.59M, missing the average forecast of $202.75M by -93.79%. Lastly, the company's EPS was $-0.83, missing the average prediction of $-1.063 by -21.94%. In terms of the last quarterly report (Dec 2023), Capricor Therapeutics's revenue was $12.09M, beating the average analysts' forecast of $10.6M by 14.04%. The company's EBITDA was $-1.063M, missing the average prediction of $-10.417M by -89.80%. Capricor Therapeutics's net income was $-762K, missing the average estimation of $-2.978M by -74.41%. The company's SG&A was $3.21M, missing the average forecast of $121.08M by -97.35%. Lastly, the company's EPS was $-0.0249, missing the average prediction of $-0.09 by -72.33%